Figure 3.
Darbepoetin affects vessels in infarct zone and angiogenic genes. (A) Left: CD31-positive vessels in infarcted region of myocardium 28 days after treatment with vehicle or darbepoetin. Right: Cd31-positive vessels in the infarct zone of mice treated with vehicle or darbepoetin (30 µg·kg−1). The bar represents 100 µm. (B) Expression of 28 angiogenic genes 24 h after myocardial infarction/sham operation and treatment with vehicle or darbepoetin. TNFSFR12a, tumour necrosis super family receptor 12a; CTGF, connective tissue growth factor; IL-10, interleukin-10; Nudt6, nudix (nucleoside diphosphate linked moiety X)-type motif 6; MMP9, matrix metalloproteinase-9; CSF-3, G-CSF; NRP1, neurophilin-1; Pofut 1, protein O-fucosyltransferase-1; PTN, pleiotrophin; CCL2, monocyte chemoattractant protein-1; Angpt14, angiopoietin-like-4; PTGS1, prostaglandin endoperoxide synthase-1; Sphk1, sphingosine kinase-1. All other genes follow standard accepted abbreviations. In (A), results are means ± SEM of five mice in each group. *P < 0.05 from sham-operated, darbepoetin-treated mice. In (B), results are means ± SEM of 10 mice in each group. *P < 0.05 from darbepoetin-treated, sham-operated mice; +P < 0.05 from infarcted, vehicle-treated mice.